Cytokinetics (CYTK) FY2022 results: revenue $95 million, up 34.3% on the year
Cytokinetics Inc. (CYTK) reported revenue of $95 million for fiscal 2022, the year ended 31 December 2022, up 34.3% on the year before. Net income was -$389 million, and diluted earnings per share $-4.33. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2023.
Revenue
$95 million
+34.3% on the year
FY2015FY2022
Operating margin
-342.8%
-264.5% a year earlier
FY2015FY2022
Net income
-$389 million
FY2015FY2022
Diluted EPS
-$4.33
FY2015FY2022
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Operating cash flow
-300
-143
8.9
Capital expenditure
11.3
48.9
11.1
-76.8%
Free cash flow
-311
-191
-2.1
Free cash flow margin
-328.6%
-271.8%
-3.8%
Cash from investing
-262
-148
-197
Cash from financing
516
320
234
+61.3%
Depreciation and amortisation
5.8
2.3
1.8
+155.4%
Share-based compensation
47.9
26.8
17.6
+78.3%
Diluted shares, weighted
90m
77m
65m
+16.8%
Shares outstanding at period end
95m
85m
71m
+11.8%
Balance sheet
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Shareholders' equity
-108
244
113
Debt
650
143
136
+354.8%
Operating lease liabilities
127
112
0.4
+13.1%
Other liabilities
346
342
284
+1.1%
Total liabilities and equity
1,015
841
534
+20.6%
Fixed assets
80.5
73.3
13.3
+9.8%
Investments
764
511
418
+49.4%
Cash and equivalents
65.6
113
83.0
-41.8%
Receivables
0.1
51.8
4.4
-99.7%
Other assets
105
92.5
15.0
+13.3%
Total assets
1,015
841
534
+20.6%
10-K for the year ended 31 December 2022, filed 1 March 2023: the filing.